ArticleArchives of dermatological research2025
Validation of the vitiligo-specific quality-of-life instrument (VitiQoL) for the Turkish language: the VitiQoL-TR study.
Article in Archives of dermatological research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Vitiligo is a generally asymptomatic acquired depigmentation disorder, limiting the utility of general dermatology quality of life (QoL) scales that may not adequately reflect the psychosocial burden experienced by patients. The aim of our study was to translate the vitiligo-specific quality-of-life instrument (VitiQoL) with maximum score of 90, into Turkish language, and to culturally adapt and validate it for use in the Turkish population. The VitiQoL was initially cross‑culturally adapted to Turkish through forward‑backward translation. The Turkish version of the VitiQoL together with the dermatology life quality index (DLQI) and the Skindex‑16 scale were applied to Turkish vitiligo patients. A total of 148 consecutive volunteer vitiligo patients were included in the study. The internal consistency of the Turkish version of the VitiQoL was excellent (Cronbach's alpha = 0.915). Since the Turkish version of the VitiQoL item 13 had a corrected item-total correlation lower than 0.3 (0.264), it was removed from the survey. VitiQoL-TR includes 14 items, with the removal of item 13 (Cronbach's alpha = 0.922). Exploratory factor analyses revealed two distinct factors within the VitiQoL scale: participation limitation and stigma. Forty-six (31.08%) of the participants completed the VitiQoL-TR twice, 10-14 days apart. The test and retest scores of the VitiQoL-TR had a strong significant correlation (r = 0.883; p < 0.001). The intraclass correlation coefficient was 0.939. There was a strong significant correlation between the VitiQoL-TR score and the Skindex-16 score (r = 0.848; p < 0.001), and a moderate significant correlation with the DLQI score (r = 0.696; p < 0.001) thus confirming the convergent validity. In conclusion, the maximum value of the scale is 84 instead of 90. This should be taken into consideration when conducting international studies and comparing international data. The VitiQoL-TR is a valid and reliable health-related QoL tool for assessing the QoL of Turkish vitiligo patients.
Indexed as
Identifiers
39987536What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.